Mercer Global Advisors
KPTI icon

Mercer Global Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Mercer Global Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-815
Closed -$42K – 2001
2022
Q4 		$42K Buy
815
+53
+7% +$3.67K ﹤0.01% 1872
2022
Q3 		$62K Buy
+762
New +$56.9K ﹤0.01% 1753

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mercer Global Advisors's KPTI Position: Q1 2023 in Review

Mercer Global Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 815 shares — an estimated $42K sold.

Mercer Global Advisors first reported a position in KPTI in Q3 2022 and held it in 2 quarters. The position peaked at $62K in Q3 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Mercer Global Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mercer Global Advisors sold 815 Karyopharm Therapeutics shares in Q1 2023, an estimated $42K.
  • Mercer Global Advisors first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 2 quarters.
  • Mercer Global Advisors's Karyopharm Therapeutics position peaked at $62K in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Mercer Global Advisors's 13F filing for Q1 2023, filed 16 May 2023.